comparemela.com

Genfit Stock Exchange News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Seal Rock Therapeutics Announces Out-Licensing Agreement with GENFIT for Development of Injectable Formulation of SRT-015 for Acute-on-Chronic Liver Disease (ACLF)

Seal Rock eligible to receive payments up to €100 million, including regulatory, clinical, and commercial milestone payments, plus tiered royalties SEATTLE, May 31, 2023 /PRNewswire/ Seal. | May 31, 2023

Pascal prigentJulie rathbunNeil mcdonnellPrnewswire seal rock therapeutics incRathbun communicationsSeal rockRock therapeuticsAcute on chronic liver failureSeal rock therapeuticsApoptosis signal reducing kinaseGenfit stock exchangePress release023 gnft fr0004163111

GENFIT Further Strengthens its ACLF Franchise with a Third Clinical-Stage Asset

Exclusive worldwide rights licensed from Seal Rock Therapeutics for injectable formulation of ASK1 Inhibitor SRT-015 in acute liver diseasePreclinical and clinical evidence support ASK1 inhibition as. | May 31, 2023

United statesUnited kingdomSeal rockFrance generalPascal prigentChronic liver failure consortiumUncertainties of the companyExchange commissionDrug administrationEuropean university hospitalsSeal rock therapeuticsAcute on chronic liver failureReactive oxygen speciesInvestigational new drugOrphan drug designationChronic liver failure

GENFIT Announces Publication of the Development and Validation of NIS2+™ in the Journal of Hepatology

Lille ; Cambridge ; Zurich ; May 23, 2023 - GENFIT , a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, today announced the. | May 23, 2023

United kingdomFrance generalUnited statesStephena harrisonStephanie boyerFounder for pinnacle clinical researchUniversity of oxfordUncertainties of the companyBiomarkers consortiumFounder of summit clinical researchFoundation for the national institutes of healthProfessor at sorbonne universityRadcliffe department of medicineExchange commissionNon alcoholic steatohepatitisVitro diagnostic

GENFIT Reports First Quarter 2023 Financial Information

Cash, cash equivalents and current financial assets totaled €128.6 million as of March 31, 2023 Lille ; Cambridge, ; Zurich ; May 11, 2023 - GENFIT , a late-stage biopharmaceutical company. | May 11, 2023

France generalUnited statesUnited kingdomUncertainties of the companyTransition services agreementExchange commissionPurchase agreementPrimary biliaryNasdaq global select marketPrivate securities litigation reform actRegistration documentGenfit stock exchangePress releaseIopharmaceutical gnft fr0004163111

GENFIT Presents Phase 1 Clinical Data Evaluating NTZ at Digestive Disease Week® as part of its ACLF Program

Lille ; Cambridge ; Zurich ; May 9, 2023 - GENFIT , a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, today announced that it is. | May 9, 2023

United statesFrance generalUnited kingdomStephanie boyerCarol addyProgram at digestive disease weekExchange commissionAmerican gastroenterological associationUncertainties of the companyAmerican society for gastrointestinal endoscopySociety for surgery of the alimentary tractAcute on chronic liver failureDigestive disease weekChronic liver failureDisease weekAmerican association

vimarsana © 2020. All Rights Reserved.